<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168278">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02056899</url>
  </required_header>
  <id_info>
    <org_study_id>423140-2</org_study_id>
    <nct_id>NCT02056899</nct_id>
  </id_info>
  <brief_title>Maintenance Gabapentin to Prolong Pregnancy.</brief_title>
  <official_title>Effect of Maintenance Gabapentin Therapy on the Rate of Premature Birth in Women With Preterm Labor After Receiving Tocolysis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University at Buffalo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University at Buffalo</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study to evaluate the tolerability and effects of maintenance gabapentin
      therapy on the rate of premature birth in women who have had preterm labor.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Rate of premature birth (before 37 weeks gestation)</measure>
    <time_frame>At delivery</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Preterm Labor, Premature Birth</condition>
  <arm_group>
    <arm_group_label>Gabapentin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <arm_group_label>Gabapentin</arm_group_label>
    <other_name>Neurontin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Eligibility Criteria:

          1. Healthy 18-45 year old female with singleton pregnancy, 20-34 weeks gestation,
             without ruptured membranes.

          2. Preterm labor defined as regular uterine contractions of at least 6/hour for ≥ 1 hour
             with ≥ 1cm of cervical dilation or ≤ 2.5cm cervical length or any documented cervical
             change from the initial pelvic exam.

          3. Cervical dilation not more than 4cm.

          4. Initiation of a tocolytic agent (e.g. magnesium sulfate, nifedipine, indomethacin)
             within the previous 72 hours.

          5. Pregnancy not conceived through in-vitro fertilization (IVF) due to the known higher
             rates of congenital defects associated with this procedure.30

          6. No placenta praevia or abruptio placentae or cervical cerclage.

          7. No intra-uterine growth restriction or non-reassuring fetal status.

          8. No known serious fetal malformations.

          9. No chorioamnionitis or medical/psychiatric/substance abuse comorbidity that may
             complicate the pregnancy or interfere with the subject's ability to comply with study
             procedures in the opinion of Dr. Guttuso or the subject's obstetrician.

         10. No history of suicide attempt.  No suicidal thoughts over past 6 months.

         11. Not currently receiving gabapentin, pregabalin, progesterone or a known teratogenic
             medication and no known allergy to gabapentin therapy.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Thomas Guttuso, Jr., MD</last_name>
    <phone>716-829-5454</phone>
    <email>tguttuso@buffalo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University at Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Guttuso, Jr., MD</last_name>
    </contact>
    <investigator>
      <last_name>Thomas Guttuso, Jr., MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 5, 2014</lastchanged_date>
  <firstreceived_date>July 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University at Buffalo</investigator_affiliation>
    <investigator_full_name>Thomas Guttuso</investigator_full_name>
    <investigator_title>Associate Professor of Neurology</investigator_title>
  </responsible_party>
  <keyword>Preterm labor, premature birth, gabapentin</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Obstetric Labor, Premature</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gabapentin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
